Drug intelligence / Profile preview

trastuzumab-strf + docetaxel

Development stage: Unknown
Lead developer: Henlius
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

HLX02 + docetaxel is a combination therapy consisting of trastuzumab-strf (HLX02), a biosimilar of trastuzumab, and docetaxel, a chemotherapy agent. This combination is used for the treatment of HER2-positive recurrent or metastatic breast cancer. HLX02 targets the human epidermal growth factor receptor 2 (HER2) while docetaxel is a taxane chemotherapy that disrupts cell division. The combination has demonstrated equivalent efficacy and similar safety profiles to reference trastuzumab plus docetaxel in clinical trials.

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on trastuzumab-strf + docetaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on trastuzumab-strf + docetaxel.

Explore the full profile